Serotonin–dopamine interaction in the induction and maintenance of l-DOPA-induced dyskinesias
Abstract
Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Other brain regions are probably also involved in L-DOPA-induced AIMs because AIMs occur via integrative changes in multiple neurotransmitter systems throughout the CNS.
“However, other brain regions are probably also involved because L-DOPA-induced AIMs occur via integrative changes in multiple neurotransmitter systems throughout the CNS, including those present in the striatum, globus pallidus, thalamus, cortical areas, subthalamic nucleus, and cerebellum (Carta et al., 2008;Fox et al., 2008).”
From Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization (2010) · cites this paper as Carta et al., 2008
Cites
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415 · see citing works
Steinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415 · see citing works
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,869 · see citing works
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,456 · see citing works
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050 · see citing works
Description of Parkinson's Disease as a Clinical Syndrome
Fahn, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 979 · see citing works
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922 · see citing works
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865 · see citing works
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 848 · see citing works
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821 · see citing works
Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664 · see citing works
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats
Carta, M., Carlsson, T., Kirik, D., & Björklund, A. (2007) · Brain · doi:10.1093/brain/awm082 · Cited by 637 · see citing works
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.t01-1-00285.x · Cited by 615 · see citing works
E PIDEMIOLOGY OF N EURODEGENERATION
Mayeux, R. P. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.043002.094919 · Cited by 511 · see citing works
Riad, M., Garcia, S., Watkins, K. C., Jodoin, N., Doucet, �., Langlois, X., Mestikawy, S. E., Hamon, M., & Descarries, L. (2000) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(20000207)417:2 · Cited by 502 · see citing works
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478 · see citing works
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 470 · see citing works
Dopamine and serotonin: influences on male sexual behavior
Hull, E. M., Muschamp, J. W., & Sato, S. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.08.018 · Cited by 465 · see citing works
Santini, E., Valjent, E., Usiello, A., Carta, M., Borgkvist, A., Girault, J., Hervé, D., Greengard, P., & Fisone, G. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0852-07.2007 · Cited by 436 · see citing works
Langston, J. W., Irwin, I., Langston, E. B., & Forno, L. S. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90293-3 · Cited by 435 · see citing works
de la Fuente‐Fernández, R. (2004) · Brain · doi:10.1093/brain/awh290 · Cited by 404 · see citing works
Chalmers, D. T., & Watson, S. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)90748-k · Cited by 388 · see citing works
Increased D1 dopamine receptor signaling in levodopa‐induced dyskinesia
Aubert, I., Guigoni, C., Håkansson, K., Li, Q., Doveró, S., Barthe, N., Bioulac, B. H., Gross, C. E., Fisone, G., Bloch, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20296 · Cited by 386 · see citing works
Calabresi, P., Gubellini, P., Centonze, D., Picconi, B., Bernardi, G., Chergui, K., Svenningsson, P., Fienberg, A. A., & Greengard, P. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-22-08443.2000 · Cited by 379 · see citing works
Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease
Kish, S. J., Tong, J., Hornykiewicz, O., Rajput, A. H., Chang, L.-J., Guttman, M., & Furukawa, Y. (2007) · Brain · doi:10.1093/brain/awm239 · Cited by 376 · see citing works
Dunah, A. W., & Standaert, D. G. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-15-05546.2001 · Cited by 374 · see citing works
DAncing past the DAT at a DA synapse
Cragg, S. J., & Rice, M. E. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.03.011 · Cited by 373 · see citing works
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule.
Yabut, J. M., Crane, J., Green, A. E., Keating, D., Khan, W., & Steinberg, G. (2019) · Endocrine reviews · doi:10.1210/er.2018-00283 · Cited by 355 · see citing works
Andersson, M., Hilbertson, A., & Cenci, M. A. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0259 · Cited by 350 · see citing works
Serotonin and the sleep/wake cycle: special emphasis on microdialysis studies
Portas, C. M., Bjorvatn, B., & Ursin, R. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00097-5 · Cited by 339 · see citing works
L-Dopa: Effect on Concentrations of Dopamine, Norepinephrine, and Serotonin in Brains of Mice
Everett, G. M., & Borcherding, J. W. (1970) · Science · doi:10.1126/science.168.3933.849 · Cited by 333 · see citing works
L-Dopa-Induced Release of Cerebral Monoamines
Ng, K. Y., Chase, T. N., Colburn, R. W., & Kopin, I. J. (1970) · Science · doi:10.1126/science.170.3953.76 · Cited by 331 · see citing works
Jacobs, B. L., & Fornal, C. A. (1997) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(97)80141-9 · Cited by 311 · see citing works
Serotonin in Parkinson's disease
Politis, M., & Niccolini, F. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.037 · Cited by 307 · see citing works
Tanaka, H., Kannari, K., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (1999) · Neuroreport · doi:10.1097/00001756-199902250-00034 · Cited by 302 · see citing works
Elsworth, J. D., & Roth, R. H. (1997) · Experimental Neurology · doi:10.1006/exnr.1996.6379 · Cited by 282 · see citing works
Langston, J. W., & Ballard, P. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046333 · Cited by 281 · see citing works
Venton, B. J., Zhang, H., Garris, P. A., Phillips, P. E. M., Sulzer, D., & Wightman, R. M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02109.x · Cited by 281 · see citing works
A Critical Interaction between NR2B and MAGUK in l-DOPA Induced Dyskinesia
Gardoni, F., Picconi, B., Ghiglieri, V., Polli, F., Bagetta, V., Bernardi, G., Cattabeni, F., Luca, M. D., & Calabresi, P. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.5326-05.2006 · Cited by 268 · see citing works
Molecular and anatomical organization of the dorsal raphe nucleus
Huang, K. W., Ochandarena, N. E., Philson, A. C., Hyun, M., Birnbaum, J. E., Cicconet, M., & Sabatini, B. L. (2019) · eLife · doi:10.7554/elife.46464 · Cited by 267 · see citing works
Cholinergic Dysfunction in Parkinson’s Disease
Müller, M. L. T. M., & Bohnen, N. I. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0377-9 · Cited by 264 · see citing works
Lindgren, H. S., Andersson, D. R., Lagerkvist, S., Nissbrandt, H., & Cenci, M. A. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06556.x · Cited by 264 · see citing works
Dunah, A. W., Wang, Y., Yasuda, R. P., Kameyama, K., Huganir, R. L., Wolfe, B. B., & Standaert, D. G. (2000) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23206-5 · Cited by 262 · see citing works
Maladaptive plasticity of serotonin axon terminals in levodopa‐induced dyskinesia
Ottosson, D. R., Parent, M., O’Sullivan, S. S., Doveró, S., Lees, A. J., Bézard, E., Descarries, L., & Cenci, M. A. (2010) · Annals of Neurology · doi:10.1002/ana.22097 · Cited by 262 · see citing works
Goetz, C. G., Damier, P., Hicking, C., LASKA, E. M., Müller, T. H., Olanow, C. W., Rascol, O., & Russ, H. (2006) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260 · see citing works
Serotonin in Pain and Analgesia: Actions in the Periphery
Sommer, C. (2004) · Molecular Neurobiology · doi:10.1385/mn:30:2:117 · Cited by 256 · see citing works
Hu, H. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014106 · Cited by 253 · see citing works
MPTP-induced parkinsonism in human and non-human primates--clinical and experimental aspects.
Langston, J. W., Langston, E. B., & Irwin, I. (1984) · PubMed · Cited by 252 · see citing works
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients
Politis, M., Wu, K., Loane, C., Brooks, D. J., Kiferle, L., Turkheimer, F., Bain, P. G., Molloy, S., & Piccini, P. P. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71640 · Cited by 245 · see citing works
Toward a unified theory of serotonin dysregulation in eating and related disorders
Brewerton, T. D. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00001-5 · Cited by 245 · see citing works
Differential effects of 5-hydroxytryptamine1A selective drugs on the 5-HT behavioral syndrome
Smith, L. M., & Peroutka, S. J. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90477-6 · Cited by 245 · see citing works
Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study
Politis, M., Wu, K., Loane, C., Kiferle, L., Molloy, S., Brooks, D. J., & Piccini, P. P. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.028 · Cited by 242 · see citing works
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241 · see citing works
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia
Muñoz, A., Li, Q., Gardoni, F., Marcello, E. E., Qin, C., Carlsson, T., Kirik, D., Luca, M. D., Björklund, A., Bézard, E., et al. (2008) · Brain · doi:10.1093/brain/awn235 · Cited by 241 · see citing works
Lavoie, B. A., & Parent, A. (1990) · The Journal of Comparative Neurology · doi:10.1002/cne.902990102 · Cited by 239 · see citing works
Peter, D., Jimenez, J., Liu, Y., Kim, M., & Edwards, R. H. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)37272-1 · Cited by 227 · see citing works
Sari, Y., Miquel, M., Brisorgueil, M., Ruiz, G., Doucet, E., Hamon, M., & Vergé, D. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00256-5 · Cited by 222 · see citing works
Maladaptive striatal plasticity in l-DOPA-induced dyskinesia
Cenci, M. A., & Konradi, C. L. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83011-0 · Cited by 216 · see citing works
Hajós, M., Hajós‐Korcsok, É., & Sharp, T. (1999) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0702510 · Cited by 210 · see citing works
Continuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208 · see citing works
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia
Lundblad, M., Usiello, A., Carta, M., Håkansson, K., Fisone, G., & Cenci, M. A. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.02.002 · Cited by 202 · see citing works
Hallett, P. J., Dunah, A. W., Ravenscroft, P., Zhou, S., Bezard, E., Crossman, A. R., Brotchie, J. M., & Standaert, D. G. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.11.008 · Cited by 192 · see citing works
Carlsson, T., Carta, M., Winkler, C., Björklund, A., & Kirik, D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2079-07.2007 · Cited by 191 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.012 · Cited by 187 · see citing works
Serotonin neurons, neuroplasticity, and homeostasis of neural tissue
Azmitia, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00022-6 · Cited by 184 · see citing works
Arai, R., Karasawa, N., Geffard, M., & Nagatsu, I. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11817-g · Cited by 184 · see citing works
Chase, T. N. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s17 · Cited by 180 · see citing works
Dunah, A. W., Sirianni, A. C., Fienberg, A. A., Bastia, E., Schwarzschild, M. A., & Standaert, D. G. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.1.121 · Cited by 175 · see citing works
Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T. J., Nutt, J. G., Rascol, O., Serbanescu, A., Deckers, F., & Russ, H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200403000-00003 · Cited by 175 · see citing works
Serotonin control of central dopaminergic function: focus on in vivo microdialysis studies
DIMATTEO, V., Giovanni, G. D., Pierucci, M., & Esposito, E. (2008) · Progress in brain research · doi:10.1016/s0079-6123(08)00902-3 · Cited by 170 · see citing works
Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study
Svenningsson, P., Rosenblad, C., Arvidsson, K. A. E., Wictorin, K., Keywood, C., Shankar, B., Lowe, D. A., Björklund, A., & Widner, H. (2015) · Brain · doi:10.1093/brain/awu409 · Cited by 162 · see citing works
Striatal synaptic plasticity: Implications for motor learning and Parkinson's disease
Pisani, A., Centonze, D., Bernardi, G., & Calabresi, P. (2005) · Movement Disorders · doi:10.1002/mds.20394 · Cited by 161 · see citing works
Effects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
Bara‐Jimenez, W., Bibbiani, F., Morris, M. J., Dimitrova, T. D., Sherzai, A., Mouradian, M. M., & Chase, T. N. (2005) · Movement Disorders · doi:10.1002/mds.20370 · Cited by 157 · see citing works
Arai, R., Karasawa, N., Geffard, M., Nagatsu, T., & Nagatsu, I. (1994) · Brain Research · doi:10.1016/0006-8993(94)91511-3 · Cited by 156 · see citing works
Robelet, S., Melon, C., Guillet, B. A., Salin, P., & Goff, L. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03591.x · Cited by 150 · see citing works
Amantadine for dyskinesia in Parkinson's disease
Crosby, N. J., Deane, K. H., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003467 · Cited by 146 · see citing works
Progression of monoaminergic dysfunction in parkinson's disease: a longitudinal 18f-dopa pet study
Pavese, N., Rivero-Bosch, M., Lewis, S. J., Whone, A. L., & Brooks, D. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.03.012 · Cited by 145 · see citing works
Cersosimo, M. G., & Benarroch, E. E. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.09.030 · Cited by 145 · see citing works
Jaunarajs, K. L. E., Gupta, V., Alam, S., Park, J. Y., & Bishop, C. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.05.002 · Cited by 144 · see citing works
Nicholson, S. L., & Brotchie, J. M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.1.x · Cited by 142 · see citing works
Tahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141 · see citing works
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia
Bézard, E., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Movement Disorders · doi:10.1002/mds.25366 · Cited by 136 · see citing works
Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates
Guigoni, C., Doudnikoff, É., Li, Q., Bloch, B., & Bézard, E. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.02.001 · Cited by 136 · see citing works
Kannari, K., Yamato, H., Shen, H., Tomiyama, M., Suda, T., & Matsunaga, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00184.x · Cited by 133 · see citing works
Bibbiani, F., Oh, J. D., Kielaitė, A., Collins, M. A., Smith, C., & Chase, T. N. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.017 · Cited by 130 · see citing works
Jaunarajs, K. L. E., Angoa‐Pérez, M., Kuhn, D. M., & Bishop, C. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.06.007 · Cited by 129 · see citing works
Westin, J. E., Andersson, M., Lundblad, M., & Cenci, M. A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01743.x · Cited by 129 · see citing works
Maeda, T., Nagata, K., Yoshida, Y., & Kannari, K. (2005) · Brain Research · doi:10.1016/j.brainres.2005.04.019 · Cited by 126 · see citing works
Ceci, A., Baschirotto, A., & Borsini, F. (1994) · Neuropharmacology · doi:10.1016/0028-3908(94)90177-5 · Cited by 126 · see citing works
Jaunarajs, K. L. E., Dupre, K. B., Barnum, C. J., Dickinson, S. O., Park, J. Y., & Bishop, C. (2009) · Synapse · doi:10.1002/syn.20630 · Cited by 124 · see citing works
The role of 5‐HT1B receptors in the regulation of serotonin cell firing and release in the rat brain
Adell, A., Celada, P., & Artigas, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00550.x · Cited by 123 · see citing works
Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex
Casanovas, J. M., Hervás, I., & Artigas, F. (1999) · Neuroreport · doi:10.1097/00001756-199905140-00010 · Cited by 118 · see citing works
Iravani, M., Tayarani-Binazir, K. A., Chu, W. B., Jackson, M., & Jenner, P. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110429 · Cited by 115 · see citing works
l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation
Picconi, B., Paillé, V., Ghiglieri, V., Bagetta, V., Barone, I., Lindgren, H. S., Bernardi, G., Cenci, M. A., & Calabresi, P. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.001 · Cited by 115 · see citing works
Presynaptic mechanisms of motor fluctuations in Parkinson’s disease: a probabilistic model
de la Fuente‐Fernández, R., Schulzer, M., Mak, E., Calne, D. B., & Stoessl, A. J. (2004) · Brain · doi:10.1093/brain/awh102 · Cited by 112 · see citing works
Mura, A., Jackson, D., Manley, M. S., Young, S. J., & Groves, P. M. (1995) · Brain Research · doi:10.1016/0006-8993(95)01104-8 · Cited by 112 · see citing works
PET demonstrates reduced dopamine transporter expression in PD with dyskinesias
Troiano, A. R., de la Fuente‐Fernández, R., Sossi, V., Schulzer, M., Mak, E., Ruth, T. J., & Stoessl, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000338631.73211.56 · Cited by 110 · see citing works
Olanow, C. W., & Obeso, J. A. (2000) · PubMed · Cited by 107 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102 · see citing works
Knobelman, D. A., Kung, H. F., & Lucki, I. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35396-0 · Cited by 99 · see citing works
Presynaptic dopamine depletion predicts levodopa-induced dyskinesia in de novo Parkinson disease
Hong, J. Y., Oh, J. S., Lee, I., Sunwoo, M. K., Ham, J. H., Lee, J. E., Sohn, Y. H., Kim, J. S., & Lee, P. H. (2014) · Neurology · doi:10.1212/wnl.0000000000000385 · Cited by 96 · see citing works
Goodwin, G. M., Souza, R. J. D., Wood, A. J., & Green, A. R. (1986) · Psychopharmacology · doi:10.1007/bf00174066 · Cited by 96 · see citing works
Muñoz, A., Carlsson, T., Tronci, E., Kirik, D., Björklund, A., & Carta, M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.05.033 · Cited by 94 · see citing works
Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum
Lopez, A., Muñoz, A., Guerra, M. J., & Labandeira-García, J. L. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00588-1 · Cited by 91 · see citing works
Kannari, K., Tanaka, H., Maeda, T., Tomiyama, M., Suda, T., & Matsunaga, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740263.x · Cited by 85 · see citing works
The behavioural effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in mice
Yamada, J., Sugimoto, Y., & Horisaka, K. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90205-1 · Cited by 84 · see citing works
Guigoni, C., Li, Q., Aubert, I., Doveró, S., Bioulac, B. H., Bloch, B., Crossman, A. R., Gross, C. E., & Bézard, E. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.5059-04.2005 · Cited by 84 · see citing works
Fiorentini, C., Rizzetti, M. C., Busi, C., Bontempi, S., Collo, G., Spano, P., & Missale, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.016667 · Cited by 82 · see citing works
Iderberg, H., McCreary, A. C., Varney, M. A., Kleven, M. S., Koek, W., Bardin, L., Depoortère, R., Cenci, M. A., & Newman‐Tancredi, A. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.05.021 · Cited by 80 · see citing works
Arai, R., Karasawa, N., & Nagatsu, I. (1996) · Brain Research · doi:10.1016/0006-8993(95)01281-8 · Cited by 80 · see citing works
Aromatic L‐amino acid decarboxylase in rat corpus striatum
Melamed, E., Hefti, F. F., Pettibone, D. J., Liebman, J., & Wurtman, R. J. (1981) · Neurology · doi:10.1212/wnl.31.6.651 · Cited by 80 · see citing works
Serotonin-to-dopamine transporter ratios in Parkinson disease
Roussakis, A., Politis, M., Towey, D., & Piccini, P. P. (2016) · Neurology · doi:10.1212/wnl.0000000000002494 · Cited by 79 · see citing works
Bishop, C., George, J. A., Buchta, W. C., Goldenberg, A. A., Mohamed, M., Dickinson, S. O., Eissa, S., & Jaunarajs, K. L. E. (2012) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2012.08202.x · Cited by 75 · see citing works
López-Real, A. M., Rodríguez‐Pallares, J., Guerra, M. J., & Labandeira-García, J. L. (2003) · Brain Research · doi:10.1016/s0006-8993(03)02291-1 · Cited by 75 · see citing works
Carey, R. J., DePalma, G., Damianopoulos, E. N., M�ller, C., & Huston, J. P. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1917-4 · Cited by 74 · see citing works
Effects of sarizotan on the corticostriatal glutamate pathways
Antonelli, T., Fuxé, K., Tomasini, M. C., Bartoszyk, G. D., Seyfried, C. A., Tanganelli, S., & Ferraro, L. (2005) · Synapse · doi:10.1002/syn.20195 · Cited by 74 · see citing works
Do serotonin1–7 receptors modulate short and long-term memory?
Meneses, A. (2007) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2006.12.005 · Cited by 74 · see citing works
Chase, T. N., Ng, L. K. Y., & Watanabe, A. M. (1972) · Neurology · doi:10.1212/wnl.22.5.479 · Cited by 69 · see citing works
Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.
Hollister, A. S., Breese, G. R., & Mueller, R. A. (1979) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)31520-x · Cited by 68 · see citing works
Serotonin receptors in brain revisited
Palacios, J. M. (2015) · Brain Research · doi:10.1016/j.brainres.2015.12.042 · Cited by 67 · see citing works
Levodopa Infusion Therapy in Parkinson Disease
Nyholm, D., & Aquilonius, S. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000144041.28224.b7 · Cited by 66 · see citing works
Conti, M. M., Ostock, C. Y., Lindenbach, D., Goldenberg, A. A., Kampton, E. B., Dell'isola, R., Katzman, A. C., & Bishop, C. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.017 · Cited by 66 · see citing works
Ultrastructure of Secretory and High-Polymer Serum Immunoglobulin A of Human and Rabbit Origin
Svehag, S., & Bloth, B. (1970) · Science · doi:10.1126/science.168.3933.847 · Cited by 66 · see citing works
Behavioural impact of a double dopaminergic and serotonergic lesion in the non-human primate
Beaudoin‐Gobert, M., Epinat‐Duclos, J., Météreau, É., Duperrier, S., Neumane, S., Ballanger, B., Lavenne, F., Liger, F., Tourvielle, C., Bonnefoi, F., et al. (2015) · Brain · doi:10.1093/brain/awv183 · Cited by 65 · see citing works
Sellnow, R. C., Newman, J. H., Chambers, N., West, A. R., Steece‐Collier, K., Sandoval, I. M., Benskey, M. J., Bishop, C., & Manfredsson, F. P. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0653-7 · Cited by 64 · see citing works
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2005) · Movement Disorders · doi:10.1002/mds.20654 · Cited by 63 · see citing works
Kannari, K., Shen, H., Arai, A., Tomiyama, M., & Baba, M. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.03.059 · Cited by 62 · see citing works
Putaminal serotonergic innervation
Lee, J., Seo, S., Lee, J. S., Kim, H., Kim, Y. K., & Jeon, B. S. (2015) · Neurology · doi:10.1212/wnl.0000000000001909 · Cited by 59 · see citing works
Engeln, M., Deurwaerdère, P. D., Li, Q., Bézard, E., & Fernagut, P. (2014) · Cerebral Cortex · doi:10.1093/cercor/bhu076 · Cited by 58 · see citing works
Tronci, E., Napolitano, F., Muñoz, A., Fidalgo, C., Rossi, F., Björklund, A., Usiello, A., & Carta, M. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.07.017 · Cited by 57 · see citing works
Tronci, E., Lisci, C., Stancampiano, R., Fidalgo, C., Collu, M., Devoto, P., & Carta, M. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.014 · Cited by 55 · see citing works
Effects of L-Dopa on Efflux of Cerebral Monoamines from Synaptosomes
Ng, K. Y., Colburn, R. W., & Kopin, I. J. (1971) · Nature · doi:10.1038/230331a0 · Cited by 54 · see citing works
Masuhr, F., Wissel, J., M�ller, J., Scholz, U., & Poewe, W. H. (2000) · Movement Disorders · doi:10.1002/1531-8257(200009)15:5 · Cited by 54 · see citing works
Ulusoy, A., Şahin, G., & Kirik, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003432107 · Cited by 52 · see citing works
Fidalgo, C., Ko, W. K. D., Tronci, E., Li, Q., Stancampiano, R., Chuan, Q., Bézard, E., & Carta, M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.04.027 · Cited by 50 · see citing works
Jackson, M. J., Al‐Barghouthy, G., Pearce, R. K. B., Smith, L. A., Hagan, J. J., & Jenner, P. G. (2004) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.07.015 · Cited by 50 · see citing works
Mignon, L., & Wolf, W. A. (2005) · Neuroreport · doi:10.1097/00001756-200505120-00009 · Cited by 48 · see citing works
Pasquini, J., Ceravolo, R., Brooks, D. J., Bonuccelli, U., & Pavese, N. (2019) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2019.03.025 · Cited by 47 · see citing works
Smith, R., Wu, K., Hart, T., Loane, C., Brooks, D., Björklund, A., Odin, P., Piccini, P., & Politis, M. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.12.037 · Cited by 43 · see citing works
Huot, P., Johnston, T. H., Fox, S. H., Newman‐Tancredi, A., & Brotchie, J. M. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.05.033 · Cited by 42 · see citing works
Morissette, M., Dridi, M., Calon, F., Tahar, A. H., Meltzer, L. T., Bédard, P. J., & Paolo, T. D. (2006) · Synapse · doi:10.1002/syn.20295 · Cited by 41 · see citing works
Hughes, J. H., Dunne, F. J., & Young, A. H. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.177.5.447 · Cited by 41 · see citing works
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective
Carta, M., & Björklund, A. (2018) · Journal of Neural Transmission · doi:10.1007/s00702-018-1865-5 · Cited by 40 · see citing works
Meloni, M., Puligheddu, M., Carta, M., Cannas, A., Figorilli, M., & Defazio, G. (2020) · European Journal of Neurology · doi:10.1111/ene.14179 · Cited by 40 · see citing works
Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease
Mazzucchi, S., Frosini, D., Ripoli, A., Nicoletti, V., Linsalata, G., Bonuccelli, U., & Ceravolo, R. (2014) · Acta Neurologica Scandinavica · doi:10.1111/ane.12314 · Cited by 38 · see citing works
Premotor Symptoms and Early Diagnosis of Parkinson's Disease
Adler, C. H. (2011) · International Journal of Neuroscience · doi:10.3109/00207454.2011.620192 · Cited by 34 · see citing works
Arai, R., Karasawa, N., Nagatsu, T., & Nagatsu, I. (1995) · Brain Research · doi:10.1016/0006-8993(94)01259-k · Cited by 33 · see citing works
Pöldinger, W., Calanchini, B., & Schwarz, W. (2010) · Psychopathology · doi:10.1159/000284698 · Cited by 32 · see citing works
Lin, J. Y., Dubey, R., Funk, G. D., & Lipski, J. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03757-5 · Cited by 30 · see citing works
Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats
Conti, M. M., Meadows, S. M., Melikhov-Sosin, M., Lindenbach, D., Hallmark, J., Werner, D. F., & Bishop, C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.07.025 · Cited by 29 · see citing works
Depoortère, R., Bardin, L., Varney, M. A., & Newman‐Tancredi, A. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00661 · Cited by 26 · see citing works
Meloni, M., Puligheddu, M., Sanna, F., Cannas, A., Farris, R., Tronci, E., Figorilli, M., Defazio, G., & Carta, M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116869 · Cited by 26 · see citing works
Jangid, P., Malik, P., Singh, P., Sharma, M., & Gulia, A. (2012) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2012.05.011 · Cited by 25 · see citing works
Serotonin Neurons, Neuroplasticity, and Homeostasis of Neural Tissue
Azmitia, E. C. (1999) · Neuropsychopharmacology · doi:10.1038/sj.npp.1395346 · Cited by 24 · see citing works
Tronci, E., Fidalgo, C., Stancampiano, R., & Carta, M. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.06.034 · Cited by 21 · see citing works
Bézard, E., & Carta, M. (2015) · Brain · doi:10.1093/brain/awu407 · Cited by 18 · see citing works
Flagged first, then by citations
1 of the 157 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Functional Neuroanatomy of the Basal GangliaPreprint
Lanciego, J. L., Luquin, N., & Obeso, J. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009621 · Cited by 847 · see citing works
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease
Bastide, M. F., Meissner, W. G., Picconi, B., Fasano, S., Fernagut, P., Feyder, M. T., Francardo, V., Alcacer, C., Ding, Y., Brambilla, R., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.07.002 · Cited by 470 · see citing works
Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap
Calabresi, P., Filippo, M. D., Ghiglieri, V., Tambasco, N., & Picconi, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70218-0 · Cited by 390 · see citing works
The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinson’s Disease
Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H., & Brotchie, J. M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005678 · Cited by 324 · see citing works
Darmopil, S., Martín, A. B., Ruiz‐DeDiego, I., Ares‐Santos, S., & Moratalla, R. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.025 · Cited by 267 · see citing works
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195 · see citing works
α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s Disease
Quik, M., & Wonnacott, S. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003269 · Cited by 194 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.01.012 · Cited by 187 · see citing works
Levodopa-Induced Dyskinesia in Parkinson’s Disease: Pathogenesis and Emerging Treatment Strategies
Kwon, D. K., Kwatra, M., Wang, J., & Ko, H. S. (2022) · Cells · doi:10.3390/cells11233736 · Cited by 175 · see citing works
Deurwaerdère, P. D., & Giovanni, G. D. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.03.004 · Cited by 164 · see citing works
Huot, P., Johnston, T. H., Darr, T., Hazrati, L., Visanji, N. P., Pires, D., Brotchie, J. M., & Fox, S. H. (2010) · Movement Disorders · doi:10.1002/mds.23083 · Cited by 153 · see citing works
Multiple roles for nicotine in Parkinson's disease
Quik, M., Huang, L. Z., Parameswaran, N., Bordia, T., Campos, C., & Perez, X. A. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.05.003 · Cited by 134 · see citing works
Levodopa-induced plasticity: a double-edged sword in Parkinson's disease?
Calabresi, P., Ghiglieri, V., Mazzocchetti, P., Corbelli, I., & Picconi, B. (2015) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2014.0184 · Cited by 114 · see citing works
Navailles, S., Benazzouz, A., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.5031-09.2010 · Cited by 106 · see citing works
Serotonin and dopamine striatal innervation in Parkinson’s disease and Huntington’s chorea
Bédard, C., Wallman, M., Pourcher, E., Gould, P. V., Parent, A., & Parent, M. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.05.012 · Cited by 103 · see citing works
Navailles, S., Bioulac, B. H., Gross, C. E., & Deurwaerdère, P. D. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.007 · Cited by 102 · see citing works
Fiorino, F., Severino, B., Magli, E., Ciano, A., Caliendo, G., Santagada, V., Frecentese, F., & Perissutti, E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400533t · Cited by 90 · see citing works
Jaunarajs, K. L. E., Dupre, K. B., Ostock, C. Y., Button, T., Terrence Deak, B., & Bishop, C. (2010) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32833e7e80 · Cited by 87 · see citing works
Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression
Riederer, P. F., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X. M., Löschmann, P. A., Sian‐Hülsmann, J., Jost, W. H., Müller, T. H., Dijkstra, J. M., et al. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02893-4 · Cited by 96 · see citing works
Newman‐Tancredi, A., Depoortère, R., Kleven, M. S., Kołaczkowski, M., & Zimmer, L. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107937 · Cited by 83 · see citing works
Bastide, M. F., Doveró, S., Charron, G., Porras, G., Gross, C. E., Fernagut, P., & Bézard, E. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.020 · Cited by 82 · see citing works
Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization
Bordia, T., Campos, C., McIntosh, J. M., & Quik, M. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.162396 · Cited by 82 · see citing works
The serotonergic system in motor and non-motor manifestations of Parkinson’s disease
Huot, P., & Fox, S. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3621-2 · Cited by 83 · see citing works
Muñoz, A., López-López, A., Labandeira, C. M., & Labandeira-García, J. L. (2020) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2020.00026 · Cited by 78 · see citing works
Carta, M., & Tronci, E. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00078 · Cited by 72 · see citing works
Brazhnik, E. S., Novikov, N., McCoy, A. J., Cruz, A. V., & Walters, J. R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.07.010 · Cited by 63 · see citing works
Nicotine reduces established levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Quik, M., Mallela, A., Ly, J., & Zhang, D. (2013) · Movement Disorders · doi:10.1002/mds.25594 · Cited by 60 · see citing works
Ghiglieri, V., Mineo, D., Vannelli, A., Cacace, F., Mancini, M., Pendolino, V., Napolitano, F., di Maio, A., Mellone, M., Stanic, J., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.11.022 · Cited by 58 · see citing works
Castagnola, E., Garg, R., Rastogi, S. K., Cohen‐Karni, T., & Cui, X. T. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113440 · Cited by 56 · see citing works
Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies
Sharma, S., Singh, S., Sharma, V., Singh, V. P., & Deshmukh, R. R. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.029 · Cited by 56 · see citing works
Bandopadhyay, R., Mishra, N., Rana, R., Kaur, G., Ghoneim, M. M., Alshehri, S., Mustafa, G., Ahmad, J., Alhakamy, N. A., & Mishra, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.805388 · Cited by 55 · see citing works
Schaeffer, E., Pilotto, A., & Berg, D. (2014) · CNS Drugs · doi:10.1007/s40263-014-0205-z · Cited by 54 · see citing works
Nondopaminergic Treatments for Parkinson’s Disease: Current and Future Prospects
Freitas, M. E., & Fox, S. H. (2016) · Neurodegenerative Disease Management · doi:10.2217/nmt-2016-0005 · Cited by 53 · see citing works
Navailles, S., Lagière, M., Contini, A., & Deurwaerdère, P. D. (2013) · ACS Chemical Neuroscience · doi:10.1021/cn400046e · Cited by 52 · see citing works
Cell transplantation and gene therapy in Parkinson's disease.
Wakeman, D. R., Dodiya, H. B., & Kordower, J. (2011) · The Mount Sinai journal of medicine, New York · doi:10.1002/msj.20233 · Cited by 60 · see citing works
5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA
Huot, P., Johnston, T. H., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.04.035 · Cited by 50 · see citing works
Fisher, R., Hikima, A., Morris, R. H., Jackson, M. J., Rose, S., Varney, M. A., Depoortère, R., & Newman‐Tancredi, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107997 · Cited by 50 · see citing works
Lohr, K. M., Chen, M., Hoffman, C. A., McDaniel, M. J., Stout, K. A., Dunn, A. R., Wang, M., Bernstein, A. I., & Miller, G. W. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw106 · Cited by 48 · see citing works
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia
Bézard, E., Muñoz, A., Tronci, E., Pioli, E. Y., Li, Q., Porras, G., Björklund, A., & Carta, M. (2013) · Neuroscience Research · doi:10.1016/j.neures.2013.10.002 · Cited by 47 · see citing works
Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia
Navailles, S., & Deurwaerdère, P. D. (2011) · Parkinson s Disease · doi:10.1155/2012/323686 · Cited by 47 · see citing works
S100B Transgenic Mice Develop Features of Parkinson's Disease
Liu, J., Wang, H., Zhang, L., Xu, Y., Deng, W., Zhu, H., & Qin, C. (2011) · Archives of Medical Research · doi:10.1016/j.arcmed.2011.01.005 · Cited by 46 · see citing works
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 45 · see citing works
ABT‐089 and ABT‐894 reduce levodopa‐induced dyskinesias in a monkey model of Parkinson's disease
Zhang, D., Bordia, T., McGregor, M. M., McIntosh, J. M., Decker, M. W., & Quik, M. (2014) · Movement Disorders · doi:10.1002/mds.25817 · Cited by 45 · see citing works
Dominguez‐Meijide, A., Villar‐Cheda, B., Garrido‐Gil, P., Sierrra-Paredes, G., Guerra, M. J., & Labandeira-García, J. L. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.07.016 · Cited by 45 · see citing works
Quik, M., Mallela, A., Chin, M. C., McIntosh, J. M., Perez, X. A., & Bordia, T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.006 · Cited by 45 · see citing works
Serotonin hyperinnervation of the striatum with high synaptic incidence in parkinsonian monkeys
Gagnon, D., Grégoire, L., Paolo, T. D., & Parent, M. (2015) · Brain Structure and Function · doi:10.1007/s00429-015-1125-5 · Cited by 44 · see citing works
Huot, P., Fox, S. H., Newman‐Tancredi, A., & Brotchie, J. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.184093 · Cited by 44 · see citing works
Quik, M., Campos, C., Bordia, T., Strachan, J., Zhang, J., McIntosh, J. M., Letchworth, S. R., & Green-Jordan, K. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.03.038 · Cited by 43 · see citing works
Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque
Huot, P., Johnston, T. H., Koprich, J. B., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.09.011 · Cited by 43 · see citing works
Huot, P., Johnston, T. H., Gandy, M. N., Reyes, M. G., Fox, S. H., Piggott, M., & Brotchie, J. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045587 · Cited by 40 · see citing works
Stievenard, A., Méquinion, M., Andrews, Z. B., Destée, A., Chartier-Harlin, M.-C., Viltart, O., & Vanbesien-Mailliot, C. C. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.11.021 · Cited by 39 · see citing works
Monoamine Reuptake Inhibitors in Parkinson’s Disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2015) · Parkinson s Disease · doi:10.1155/2015/609428 · Cited by 39 · see citing works
Cell-Based Therapies for Parkinson's Disease: Past, Present, and Future
Fitzpatrick, K. M., Raschke, J., & Emborg, M. E. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2654 · Cited by 37 · see citing works
Depoortère, R., Johnston, T. H., Fox, S. H., Brotchie, J. M., & Newman‐Tancredi, A. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.08.009 · Cited by 37 · see citing works
Targeting Nicotinic Receptors for Parkinson's Disease Therapy
Quik, M., Bordia, T., Huang, L. Z., & Perez, X. A. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711797247849 · Cited by 37 · see citing works
Zhang, Y., Sun, H., He, X., Wang, Y., Gao, Y.-S., Wu, H.-X., Xu, H., Gong, X., & Guo, Z. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.01.005 · Cited by 36 · see citing works
Mathematical Insights into the Effects of Levodopa
Reed, M. C., Nijhout, H. F., & Best, J. A. (2012) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2012.00021 · Cited by 35 · see citing works
Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease
Cheshire, P., & Williams, D. R. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.09.008 · Cited by 33 · see citing works
Franchini, S., Manasieva, L. I., Sorbi, C., Battisti, U. M., Fossa, P., Cichero, E., Denora, N., Iacobazzi, R. M., Cilia, A., Pirona, L., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.050 · Cited by 33 · see citing works
Depression in Parkinson's disease
Ossowska, K., & Lorenc‐Koci, E. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71516-0 · Cited by 31 · see citing works
Seibyl, J. P., Russell, D., Jennings, D. L., & MAREK, K. L. (2012) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2012.06.003 · Cited by 28 · see citing works
Wichit, P., Thanprasertsuk, S., Phokaewvarangkul, O., Bhidayasiri, R., & Bongsebandhu‐phubhakdi, S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.605887 · Cited by 27 · see citing works
Corsi, S., Stancampiano, R., & Carta, M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.032 · Cited by 27 · see citing works
The Parkinson's disease death rate: carbidopa and vitamin B6
Hinz, M., Stein, A. L., & Cole, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s70707 · Cited by 25 · see citing works
RetractedAge-Dependent Maintenance of Motor Controland Corticostriatal Innervation by Death Receptor 3
Twohig, J. P., Roberts, M. I., Gavaldà, N., Rees-Taylor, E. L., Giralt, A., Adams, D., Brooks, S. P., Bull, M. J., Calder, C. J., Cuff, S. M., et al. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.1928-09.2010 · Cited by 23 · see citing works
Bove, F., Angeloni, B. M., Sanginario, P., Rossini, P. M., Calabresi, P., & Iorio, R. D. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102548 · Cited by 22 · see citing works
Miguélez, C., Benazzouz, A., Ugedo, L., & Deurwaerdère, P. D. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00274 · Cited by 22 · see citing works
Serotonergic modulation of basal ganglia circuits
Benarroch, E. E. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b784e7 · Cited by 21 · see citing works
Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model
Aboulghasemi, N., Jahromy, M. H., & Ghasemi, A. (2018) · IBRO Reports · doi:10.1016/j.ibror.2018.12.001 · Cited by 20 · see citing works
Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update
Alshimemeri, S. A., Fox, S. H., & Visanji, N. P. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1763954 · Cited by 20 · see citing works
Ko, W. K. D., Li, Q., Cheng, L., Morelli, M., Carta, M., & Bézard, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.030 · Cited by 19 · see citing works
Parkinson's disease: carbidopa, nausea, and dyskinesia
Hinz, M., Stein, A. L., & Cole, T. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s72234 · Cited by 17 · see citing works
RetractedSvenningsson, P., Odin, P., Bergquist, F., Wirdefeldt, K., Nyholm, D., Andréasson, M., Markaki, I., Johansson, A., Jergil, M., Jankosky, C., et al. (2025) · Movement Disorders · doi:10.1002/mds.30175 · Cited by 16 · see citing works
l-DOPA- and graft-induced dyskinesia following transplantation
Lane, E. L., & Winkler, C. (2012) · Progress in brain research · doi:10.1016/b978-0-444-59575-1.00007-7 · Cited by 16 · see citing works
Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects
Peters, K. Z., Zlebnik, N. E., & Cheer, J. F. (2021) · International review of neurobiology · doi:10.1016/bs.irn.2021.07.002 · Cited by 16 · see citing works
Inhibiting Lateral Habenula Improves L-DOPA–Induced Dyskinesia
Bastide, M. F., de la Crompe, B., Doudnikoff, É., Fernagut, P., Gross, C. E., Mallet, N. P., Boraud, T., & Bézard, E. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.022 · Cited by 16 · see citing works
Serotonin as a biomarker of toxin-induced Parkinsonism
Buchanan, A. M., Mena, S., Choukari, I., Vasa, A., Crawford, J., Fadel, J. R., Maxwell, N., Reagan, L. P., Cruikshank, A. E., Best, J. A., et al. (2024) · Molecular Medicine · doi:10.1186/s10020-023-00773-9 · Cited by 15 · see citing works
López-López, A., Valenzuela, R., Rodriguez-Perez, A. I., Guerra, M. J., Labandeira-García, J. L., & Muñoz, A. (2023) · Antioxidants · doi:10.3390/antiox12071454 · Cited by 14 · see citing works
Huot, P., & Brotchie, J. M. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.07.006 · Cited by 14 · see citing works
Mahmoudi, J., Nayebi, A. M., Samini, M., Reyhani‐Rad, S., & Babapour, V. (2011) · Europe PMC (PubMed Central) · Cited by 14 · see citing works
Lettfuss, N. Y., Fischer, K., Sossi, V., Pichler, B., & von Ameln-Mayerhofer, A. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.06.051 · Cited by 13 · see citing works
Synaptic Interactions Between Serotonergic and Dopaminergic Systems in Parkinson’s Disease
Marino, G., Campanelli, F., Natale, G., Carluccio, M. D., Servillo, F., Ghiglieri, V., & Calabresi, P. (2025) · Current Neuropharmacology · doi:10.2174/011570159x336597241217062042 · Cited by 13 · see citing works
Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats
Mahmoudi, J., Nayebi, A. M., Samini, M., Reyhani‐Rad, S., & Babapour, V. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70606-5 · Cited by 13 · see citing works
Fluoxetine Improves the Effect of Levodopa on 6-Hydroxy Dopamine-Induced Motor Impairments in Rats
Mahmoudi, J., Nayebi, A. M., Reyhani-Rad, S., & Samini, M. (2012) · Europe PMC (PubMed Central) · doi:10.5681/apb.2012.023 · Cited by 13 · see citing works
Choi, Y., Huh, E., Lee, S.-M., Kim, J. H., Park, M. G., Seo, S., Kim, S. Y., & Oh, M. S. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.141 · Cited by 12 · see citing works
Budrow, C., Elder, K. K., Coyle, M., Centner, A., Lipari, N., Cohen, S. R., Glinski, J., Kinzonzi, N., Wheelis, E., McManus, G., et al. (2023) · Cells · doi:10.3390/cells12060837 · Cited by 12 · see citing works
Understanding Graft-Induced Dyskinesia
Lane, E. L., & Smith, G. A. (2010) · Regenerative Medicine · doi:10.2217/rme.10.42 · Cited by 11 · see citing works
Morin, N., Morissette, M., Grégoire, L., & Paolo, T. D. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.07.006 · Cited by 11 · see citing works
Farajdokht, F., Sadigh‐Eteghad, S., Majdi, A., Pashazadeh, F., Vatandoust, S. M., Ziaee, M., Safari, F., Karimi, P., & Mahmoudi, J. (2020) · EXCLI journal · doi:10.17179/excli2020-1024 · Cited by 11 · see citing works
Clinical and Experimental Experiences of Graft-Induced Dyskinesia
Lane, E. L. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00007-9 · Cited by 10 · see citing works
Picconi, B., Ghiglieri, V., & Calabresi, P. (2010) · Annals of Neurology · doi:10.1002/ana.22231 · Cited by 10 · see citing works
A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease
Muddapu, V. R., Vijayakumar, K., Ramakrishnan, K., & Chakravarthy, V. S. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.797127 · Cited by 9 · see citing works
Plasticity, genetics, and epigenetics in l-dopa-induced dyskinesias
Bove, F., & Calabresi, P. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00009-6 · Cited by 9 · see citing works
Tseng, K.-Y., Kuo, T., Wang, V., Huang, E. Y., Ma, K., Olson, L., Hoffer, B. J., & Chen, Y.-H. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223195 · Cited by 8 · see citing works
Lipari, N., Centner, A., Glinski, J., Cohen, S. R., Manfredsson, F. P., & Bishop, C. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105965 · Cited by 8 · see citing works
Dorsal GPi/GPe Stimulation Induced Dyskinesia in a Patient with Parkinson’s Disease
Elkouzi, A., Tsuboi, T., Burns, M. R., Eisinger, R. S., Patel, A., & Deeb, W. (2019) · PubMed Central · doi:10.7916/tohm.v0.685 · Cited by 8 · see citing works
Functional Neuroanatomy of the Normal and Pathological Basal GangliaPreprint
Lanciego, J. L., & Obeso, J. A. (2024) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041617 · Cited by 8 · see citing works
Jenner, P., Falup-Pecurariu, C., Leta, V., Vérin, M., Auffret, M., Bhidayasiri, R., Weiss, D., Borovečki, F., & Jost, W. (2023) · Journal of neural transmission · doi:10.1007/s00702-023-02655-0 · Cited by 6 · see citing works
Targeting Striatal Glutamate and Phosphodiesterases to Control L-DOPA-Induced Dyskinesia
Kochoian, B. A., Bure, C., & Papa, S. M. (2023) · Cells · doi:10.3390/cells12232754 · Cited by 7 · see citing works
Neuroinflammation and Dyskinesia: A Possible Causative Relationship?
Cardinale, A., de Iure, A., & Picconi, B. (2024) · Brain Sciences · doi:10.3390/brainsci14050514 · Cited by 7 · see citing works
- Authors
- CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A.
- Affiliations
- Lund University (SE)
- Corresponding author
- CARTA, M
- Venue
- Progress in brain research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 172
- Pages
- 465-478
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1933235205
- Cited by
- 131
- References
- 157
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 13 · 2013: 14 · 2012: 11
- FWCI
- 37.83
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Progress in brain research (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Neurology › Neurological disorders and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- serotonin, dopamine, levodopa-induced dyskinesia, Parkinson's disease, serotonergic system, serotonergic neurons, treatment options
- MeSH terms
- Animals, Clinical Trials as Topic, Dopamine, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease, Receptors, Dopamine, Receptors, Serotonin, Serotonin, Presynaptic Terminals, Protein Isoforms, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
